Clinical implications of antibiotic pharmacokinetic principles in the critically ill

被引:178
|
作者
Udy, Andrew A. [1 ,2 ]
Roberts, Jason A. [1 ,2 ]
Lipman, Jeffrey [1 ,2 ]
机构
[1] Univ Queensland, Royal Brisbane & Womens Hosp, Burns Trauma & Crit Care Res Ctr, Herston, Qld 4029, Australia
[2] Royal Brisbane & Womens Hosp, Dept Intens Care Med, Herston, Qld 4029, Australia
基金
英国医学研究理事会;
关键词
Antibiotics; Pharmacokinetics; Dosing; Critical illness; INTENSIVE-CARE-UNIT; AUGMENTED RENAL CLEARANCE; BETA-LACTAM ANTIBIOTICS; CONTINUOUS VENOVENOUS HEMOFILTRATION; STAPHYLOCOCCUS-AUREUS PNEUMONIA; VENTILATOR-ASSOCIATED PNEUMONIA; HIGH CREATININE CLEARANCE; POPULATION PHARMACOKINETICS; SEVERE SEPSIS; COLISTIN METHANESULFONATE;
D O I
10.1007/s00134-013-3088-4
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Successful antibiotic therapy in the critically ill requires sufficient drug concentrations at the site of infection that kill or suppress bacterial growth. The relationship between antibiotic exposure and achieving the above effects is referred to as pharmacokinetics/pharmacodynamics (PK/PD). The associated indices therefore provide logical targets for optimal antibiotic therapy. While dosing regimens to achieve such targets have largely been established from studies in animals and non-critically ill patients, they are often poorly validated in the ICU. Endothelial dysfunction, capillary leak, altered major organ blood flow, deranged plasma protein concentrations, extremes of body habitus, the application of extracorporeal support modalities, and a higher prevalence of intermediate susceptibility, independently, and in combination, significantly confound successful antibiotic treatment in this setting. As such, the prescription of standard doses are likely to result in sub-therapeutic concentrations, which in turn may promote treatment failure or the selection of resistant pathogens. This review article considers these issues in detail, summarizing the key changes in antibiotic PK/PD in the critically ill, and suggesting alternative dosing strategies that may improve antibiotic therapy in these challenging patients.
引用
收藏
页码:2070 / 2082
页数:13
相关论文
共 50 条
  • [1] Clinical implications of antibiotic pharmacokinetic principles in the critically ill
    Andrew A. Udy
    Jason A. Roberts
    Jeffrey Lipman
    Intensive Care Medicine, 2013, 39 : 2070 - 2082
  • [2] Pharmacological principles of antibiotic prescription in the critically ill
    Pinder, M
    Bellomo, R
    Lipman, J
    ANAESTHESIA AND INTENSIVE CARE, 2002, 30 (02) : 134 - 144
  • [3] Clinical pharmacokinetic monitoring of midazolam in critically ill patients
    Spina, Sean P.
    Ensom, Mary H. H.
    PHARMACOTHERAPY, 2007, 27 (03): : 389 - 398
  • [4] Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients
    Roberts, Jason A.
    Kirkpatrick, Carl M. J.
    Lipman, Jeffrey
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (02) : 227 - 231
  • [5] Pharmacokinetic and pharmacodynamic considerations of antibiotic therapy among critically ill adult patients with sepsis
    Lili, Holub
    Gergely, Szabo Balint
    Lorinc, Zavorszky
    Rozsa, Humpfner
    Peter, Andreka
    Balazs, Karvaly Gellert
    Botond, Lakatos
    ORVOSI HETILAP, 2024, 165 (11) : 403 - 415
  • [6] Gut dysfunction in the critically ill - mechanisms and clinical implications
    Hill, L. T.
    SOUTHERN AFRICAN JOURNAL OF CRITICAL CARE, 2013, 29 (02) : 11 - 15
  • [7] PROTEIN WASTING IN THE CRITICALLY ILL - PATHOGENESIS AND CLINICAL IMPLICATIONS
    KELLER, U
    INTENSIVE CARE MEDICINE, 1983, 9 (04) : 168 - 168
  • [8] CLINICAL AND PHARMACOKINETIC CHARACTERISTICS OF AMINOGLYCOSIDE NEPHROTOXICITY IN 201 CRITICALLY ILL PATIENTS
    SCHENTAG, JJ
    CERRA, FB
    PLAUT, ME
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1982, 21 (05) : 721 - 726
  • [9] Relevance of Pharmacokinetic and Pharmacodynamic Modeling to Clinical Care of Critically Ill Patients
    Bulitta, Juergen B.
    Landersdorfer, Cornelia B.
    Forrest, Alan
    Brown, Silvia V.
    Neely, Michael N.
    Tsuji, Brian T.
    Louie, Arnold
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2011, 12 (12) : 2044 - 2061
  • [10] CLINICAL AND PHARMACOKINETIC EVALUATION OF ORAL ACETAMINOPHEN ABSORPTION IN CRITICALLY ILL PATIENTS
    Rhoades, Abby
    Droege, Molly
    Droege, Chris
    Welch, Megan
    Ernst, Neil
    Keegan, Shaun
    Mueller, Eric
    CRITICAL CARE MEDICINE, 2015, 43 (12)